Lumicell

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Lumicell, Health/Medical/ Pharmaceuticals, 275 Washington Street , Suite 200, Newton, MA.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs.

12/12/2025

Reminder: Stop by our poster presentation today to
learn about how LumiSystem™ fluorescence guided surgery enables the reduction of second surgeries compared with standard lumpectomy surgery.1

Reference:
1. Smith K, Ferrer J, Schlossberg B, Shaitelman SF, Doros G, Smith BL. Impact of pegulicianine on radiotherapy decisions and long-term outcomes in patients undergoing breast conserving surgery. Poster presented at: San Antonio Breast Cancer Symposium; December 9-12, 2025; San Antonio, TX.

12/04/2025

Heading to San Antonio Breast Cancer Symposium? Discover what’s next in breast cancer surgery and visit our Poster Presentation on Friday, December 12th!

Title: Impact of pegulicianine on radiotherapy decisions and long-term outcomes in patients undergoing breast conserving surgery

Led by Lumicell Chief Scientific Officer, Jorge Ferrer PhD

11/26/2025

As we pause to celebrate Thanksgiving, we reflect on why we do what we do.

We’re deeply thankful for the healthcare professionals and institutions who partner with us to bring better care to their patients. Your trust drives our innovation.

We’re especially grateful to our incredible team at Lumicell whose dedication and passion help make a difference for breast cancer patients around the country.

Wishing everyone a Happy !

11/03/2025

The Lumicell team attended BayCare Quality Sharing & Innovation Day, showcasing how intraoperative imaging brings real-time cancer detection to the OR. We loved engaging with all the clinicians who share our passion for innovation and better surgical outcomes. Learn more: https://lumisystem.com/

07/07/2025

What if the surgeon had the power to see residual breast cancer during surgery and remove it in real-time? Listen to Jennifer Montes, MD, MPH, Breast Surgeon and President, Evolve Pink, paid consultant of Lumicell, share her perspective on the potential of LumiSystem™.

LumiSystem is the first and only solution for use in adult patients with breast cancer to assist surgeons in the detection of cancerous tissue within the lumpectomy cavity following removal of the primary specimen during lumpectomy surgery. LUMISIGHT (pegulicianine) and Lumicell™ Direct Visualization System (DVS) enable surgeons to detect and resect residual cancer, in real-time.

Learn more about LumiSystem: https://lumisystem.com/ #

The most common side effects with LUMISIGHT are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For Important Safety Information and complete product information, visit www.LumiSystem.com.

, ,

04/28/2025

Thank you, Dr. Andrew Chan and Dr. David Drew, for presenting our promising feasibility trial findings in gastrointestinal cancer patients at AACR 2025.

Lumicell's imaging research was discussed during the Stand Up To Cancer (SU2C) open Scientific Session "Advances in Detection and Treatment of Gastrointestinal Cancers" today (Monday, April 28).

Read our release at https://lumicell.com/news-press/

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this press release reflect Lumicell’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions, and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the regulatory process to approve pharmaceutical drugs or medical devices. Indication expansion involving gastrointestinal cancers require additional studies and FDA approval.

03/03/2025

Despite surgical advancements, up to 36% of patients require a second lumpectomy because cancer may have gone undetected.¹ However, when these second surgeries are performed, cancer is not found in up to 65% of cases.¹ This leaves patients and surgeons uncertain about the possibility of cancer remaining in the breast. Uncertainty persists even for patients who receive a report of negative margins following the initial surgery, with approximately 14% of them possibly still having cancer remaining.¹

LumiSystemᵀᴹ represents a promising advancement in surgical imaging technology that can be added to the lumpectomy procedure. Clinically proven to detect cancer that otherwise would have been missed, LumiSystem helps reduce the need for follow-up surgeries by detecting residual cancer in real-time. This capability not only spares some patients from additional procedures, but also informs the surgeon of the presence of cancer not initially detected in patients that would otherwise have had negative margins.

Learn more about LumiSystem: https://lumisystem.com/

Ask your doctor if LumiSystem is right for you.

The most common side effects with LUMISIGHTᵀᴹ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicellᵀᴹ DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

1. Dupont, et al. Ann Surg 2021.

, ,

02/18/2025

With 84% diagnostic accuracy, LumiSystem™ improved surgical outcomes in 10% of patients treated in the INSITE pivotal trial.¹⁻² By identifying cancerous tissue that would have been missed, LumiSystem offers a more comprehensive approach to breast-conserving surgery and ultimately enhances patient care. LumiSystem is used in addition to the standard of care lumpectomy.

Learn more about LumiSystem: https://lumisystem.com/

Ask your doctor if LumiSystem is right for you.

The most common side effects with LUMISIGHT™ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell™ DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

1. Diagnostic accuracy is based on true positive and true negative images detected in the LumiSystem pivotal trial
2. Smith, et al., NEJM Evidence 2023; 2(7)

, ,

02/03/2025

Lumicell’s innovative surgical imaging technology has been featured in USA Today®. Learn more about this technology and visit LearnAboutLumicell.com.

Read the full article here: https://www.usatoday.com/story/sponsor-story/lumicell-bh/2024/12/18/advances-in-breast-cancer-surgery-offer-patients-improved-surgical-outcomes/77048294007/

01/27/2025

We are proud to announce the U.S. commercial availability and first clinical use of LumiSystem™, the first and only fluorescence-guided imaging technology used during surgery for detection of residual breast cancer. This innovative system represents a significant advancement in breast-conserving surgery, enabling surgeons to achieve more complete resections and improve patient surgical outcomes.

For more information about LumiSystem™ and its capabilities, visit https://lumisystem.com/

Read the Press Release: https://lumicell.com/news-press/

The most common side effects with LUMISIGHT™ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

01/06/2025

Lumicell is pleased to announce the appointment of Jim Alecxih to its Board of Directors.

“We’re excited to welcome Jim to our Board of Directors. His extensive commercial and operational experience, along with a proven track record of success, will be invaluable to Lumicell,” said Howard Hechler, Chief Executive Officer of Lumicell. “Jim’s deep experience in the healthcare industry and diagnostic imaging aligns seamlessly with Lumicell’s mission to advance cancer detection across the continuum of solid tumors and improve surgical outcomes.”

Read the press release: https://lumicell.com/news-press/

12/13/2024

At SABCS 2024, Lumicell presented new data focused on patient benefit of using LumiSystem™ during lumpectomy. The findings suggest that patient satisfaction with cosmetic outcomes did not change following fluorescence-guided tissue removal and showed a strong preference for avoiding second surgeries. Additionally, adding LumiSystem to a lumpectomy procedure may alter radiation therapy recommendations in a subset of patients.

"The response from both the health care community and patients has been very positive as we have initiated our commercial launch of LumiSystem,” said Howard Hechler, Chief Executive Officer at Lumicell.

Read the Press Release: https://lumicell.com/news-press/

The most common side effects with LUMISIGHT™ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell™ DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

, ,

Address

275 Washington Street , Suite 200
Newton, MA
02458

Telephone

+16174041001

Website

http://www.lumicell.com/, http://www.LearnAboutLumicell.com/

Alerts

Be the first to know and let us send you an email when Lumicell posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Newton?